Technical Analysis for CLVS - Clovis Oncology, Inc.
|Grade||Last Price||% Change||Price Change|
CLVS closed down 1.15 percent on Tuesday, December 11, 2018, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical CLVS trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 11||Calm After Storm||Range Contraction||0.00%|
|Dec 11||Stochastic Reached Overbought||Strength||0.00%|
|Dec 11||Upper Bollinger Band Walk||Strength||0.00%|
|Dec 11||Wide Bands||Range Expansion||0.00%|
|Dec 11||Overbought Stochastic||Strength||0.00%|
|Dec 11||Upper Bollinger Band Touch||Strength||0.00%|
|Dec 10||MACD Bullish Centerline Cross||Bullish||-1.15%|
|Dec 10||Calm After Storm||Range Contraction||-1.15%|
|Dec 10||Upper Bollinger Band Walk||Strength||-1.15%|
|Dec 10||Wide Bands||Range Expansion||-1.15%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CLVS news...
|52 Week High||69.02|
|52 Week Low||11.5|
|200-Day Moving Average||39.6816|
|50-Day Moving Average||20.8766|
|20-Day Moving Average||17.666|
|10-Day Moving Average||19.128|
|Average True Range||1.8719|
|Chandelier Exit (Long, 3 ATRs )||17.2643|
|Chandelier Exit (Short, 3 ATRs )||19.4957|
|Upper Bollinger Band||21.9004|
|Lower Bollinger Band||13.4316|
|Percent B (%b)||0.95|
|MACD Signal Line||-0.5364|
|Market Cap||1.05 Billion|
|Num Shares||48.8 Million|
|Price-to-Earnings (P/E) Ratio||-2.41|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||23.70|
|Resistance 3 (R3)||23.85||23.25||23.33|
|Resistance 2 (R2)||23.25||22.69||23.18||23.21|
|Resistance 1 (R1)||22.37||22.34||22.07||22.22||23.08|
|Support 1 (S1)||20.89||21.21||20.59||20.74||19.88|
|Support 2 (S2)||20.29||20.86||20.22||19.75|
|Support 3 (S3)||19.41||20.29||19.63|
|Support 4 (S4)||19.26|